tbuckley/cabot-search huggingface dataset:
Abstract 2463: Overexpression of galectin-7 in mouse skin inhibits tumorigenesis
Authors: Melissa S. Simper, Megan M. Thomas, John L. Clifford, Susan M. Fischer
Journal: Cancer Research (2010)

Abstract Galectins are a family of proteins that contain conserved sequences in the carbohydrate-binding region that bind to β-galactosides. Galectin expression differs between tissues in addition to different stages of development and also has altered expression during tumor development. Galectin-7 (Gal-7) has been linked to both apoptosis and reduced cell growth in vitro, but conversely, upregulation of Gal-7 in skin has been reported in many transgenic mice that have endogenous skin tumor promoting activity in addition to being associated with an aggressive phenotype in lymphoma cells. To further investigate this conflicting evidence, the role of Gal-7 in skin carcinogenesis was examined. Gal-7 mRNA and protein levels were elevated in mouse skin after 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment, while Gal-7 stably-transfected cells showed a decrease in tumor growth when compared to vector stably-transfected cells after injection into nude mice, although no difference in cell growth in vitro was observed. Transgenic mice were then generated that overexpress a flag-tagged Gal-7 protein in the basal layer of the skin under the control of the bovine keratin 5 promoter (K5. Gal-7). These mice display no visible phenotype, but immunohistochemistry shows the transgene is present and expressed. Using a two-stage chemical carcinogenesis protocol, the K5. Gal-7 mice were shown to develop significantly fewer papillomas and squamous cell carcinomas than wild type (WT) mice, though no difference in proliferation or apoptosis was seen in response to TPA treatment. No difference in the inflammatory response to TPA was observed, with the exception of a spike in B cells 36 hours after TPA. However, untreated K5. Gal-7 mice showed a decrease in T and B cells compared to WT mice. This supports data from a reverse phase protein array that indicates annexin, which suppresses phospholipase A2 and inhibits inflammation, is upregulated in the K5. Gal-7 mice. These data suggest that overexpression of Gal-7 in the mouse skin inhibits tumorigenesis, possibly through the inhibition of inflammation. Supported by CA100140. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2463.
IT-27 * ONCOLYTIC ADENOVIRUSES-MEDIATED IMMUNE RESPONSES IN SYNGENEIC MURINE GLIOMA MODEL
Authors: J. Qiao, M. Dey, A. Chang, K. Woongki, Y. Han, L. Zhang, M. Lesniak
Journal: Neuro-Oncology (2014)

INTRODUCTION: Oncolytic adenovirus has been developed as a new experimental anticancer agent currently in clinical trials for glioma. Recent evidence suggests oncolytic viruses also have a therapeutic feature of inducing antitumor immune responses. Here we provide evidence that injection of oncolytic adenoviruses into established murine glioma leads to a conversion of immunosuppressive into immunostimulatory tumor environment. METHODS: Stereotactic orthotopic murine GL261 glioma was established in syngeneic immune competent mice. AdCMVΔ24 virus that has been shown to exhibit oncolytic effects on GL261 cells previously by our group was selected in the current studies. Using GL261 murine glioma model along with AdCMVΔ24, we evaluated the effects of viral treatment on generation of immune responses locally (in brain) and systemically (in cervical lymph nodes (cLNs) and spleens) upon viral injection into tumors. RESULTS: At 72hr post treatment, we observed a significant intracranial increase of both macrophages and NK cells. More importantly, we found that AdCMVΔ24 treatment decreased intracranial regulatory T cells (CD4+Foxp3+) at 72hr, 1 week, even at 2 weeks post viral treatment, whereas this was not observed in cLNs and spleens. In contrast to Treg cells, the frequency of CD3+CD8+ T cells were increased at 1 week and 2 weeks post treatment. We also found an increased frequency of IFN-g producing CD8+ cells, in cLNs as early as at 72hr and in brains at 2 weeks post treatment. Further, our studies demonstrated that intratumoral viral injection leads an increase of a ratio of CD4+IFN-g+T cells per CD4+Foxp3+ T cells. CONCLUSIONS: Taken together, these results suggest that intratumoral oncolytic adenovirus treatment may shift the immune response from suppressive to stimulatory through modulation of Treg cells, which could have significant impacts on the development of CRADs-based novel effective antiglioma immunotherapies.
Case 19-2008
Authors: Paul M. Busse, John R. Clark, Victorine V. Muse, Vincent Liu
Journal: New England Journal of Medicine (2008)

A 63-year-old HIV-positive man was referred to this hospital for management of a cutaneous Merkel-cell carcinoma on the forehead that metastasized to the ipsilateral preauricular and cervical lymph nodes. A treatment plan was established.
Abstract 4447: Nanoformulation of lapatinib for HER2-positive breast cancer patients with brain metastasis
Authors: Joyce S. Lee, Juntao Luo, Sonal Desai, Kit S. Lam, Tianhong Li
Journal: Cancer Research (2011)

Abstract Despite HER2-targeting agents having a reduced risk of distant relapse in early-stage breast cancer and improved systemic control in metastatic breast cancer, relapse or progression in the brain is a common and serious concern for mortality and morbidity in these HER2-positive breast cancer patients. Currently, radiation is the only effective therapy for these patients with various clinical outcomes. Thus, there is a significant unmet need to develop new therapeutic modalities to improve treatment efficacy for these patients, especially for patients who have failed radiation therapy. The objective of this project is to develop a novel nanoformulation of lapatinib for the treatment of HER2-positive breast cancer patients with brain metastasis. Lapatinib is the only FDA-approved small molecule tyrosine kinase inhibitor targeting both HER2 and epidermal growth factor receptor (EGFR). Lapatinib anecdotally induces objective response in HER2-positive breast cancer patients with brain metastasis. Current preclinical and clinic data suggest that lapatinib has limited and variable penetration through the blood-brain barrier, which is also affected by large inter-patient variations in the bioavailability of oral formulation of lapatinib. Dr. Lam's laboratory has developed a novel nanoparticle technology using oligocholic acid based micelles (telodendrimers) to load a high dose of hydrophobic drugs for cancer treatment. We have generated a stable nanoformulation of lapatinib with drug loading up to 10 mg per mL. The average particle size is less than 20 nm in diameter, which is desirable for tumor targeting due to the preferential drug accumulation at the tumor site via the enhanced permeation and retention (EPR) effect. We are currently optimizing and characterizing the physicochemical properties of several lapatinib-loaded nanoformulations. The most stable and efficacious nanoformulation of lapatinib will be selected for further preclinical testing using in vitro and in vivo models of HER2+ breast cancer. This nanoformulation of lapatinoib will be suitable for intrathecal injection as it is not affected by individual variations in oral bioavailability and penetration through the blood brain barrier. If successful, we would design a phase I/II clinical study to determine the safety and efficacy of this new nanoformulation of lapatinib for HER2+ breast cancer patients with refractory brain metastasis or meningeal disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4447. doi:10.1158/1538-7445.AM2011-4447
AGGRESSIVE LIPID-LOWERING THERAPY USING ROSUVASTATIN IMPROVES ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE
Authors: Tadateru Takayama, Takafumi Hiro, Yoshiharu Higuchi, Shunichi Yoda, Satoshi Kunimoto, Yoshiharu Yajima, Atsushi Hirayama
Journal: Journal of the American College of Cardiology (2015)
Erratum: Corrigendum: Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction
Authors: Mortimer Korf-Klingebiel, Marc R Reboll, Stefanie Klede, Torben Brod, Andreas Pich, Felix Polten, L Christian Napp, Johann Bauersachs, Arnold Ganser, Eva Brinkmann, Ines Reimann, Tibor Kempf, Hans W Niessen, Jacques Mizrahi, Hans-Joachim Schönfeld, Antonio Iglesias, Maria Bobadilla, Yong Wang, Kai C Wollert
Journal: Nature Medicine (2016)
P4-09-29: A Nomogram To Predict Prognosis in Node-Negative Breast Carcinoma.
Authors: C Mazouni, F Spyratos, S Romain, F Fina, P Bonnier, L Ouafik, P-M Martin
Journal: Cancer Research (2011)

Abstract Background: Currently, the usefulness of conventional markers for breast carcinoma is limited to assess individual outcome. A statistical model was developed to improve the prognostic accuracy using multiple conventional and emerging prognostic biomarkers. Methods: A total of 305 node-negative breast carcinomas who underwent surgery (+/− radiotherapy) but no adjuvant treatment was selected. Putative prognosis factors including age, tumor size, ER, PR, SBR grading, urokinase plasminogen activator (uPA), plasminogen activator inhibitor type 1 (PAI-1) and thymidine kinase (TK) were evaluated. The developed model was internally validated using Harrell's concordance index and calibrated. An external validation of the new model is warranted. Results: Age (p&amp;lt;0.001), PR (p= 0.02), and PAI-1(p=&amp;lt;0.001) were included in the Cox regression model predicting overall survival at 5-years. Internal validation revealed a concordance index of 0.711 to 0.694 before and after calibration. Conclusion: A nomogram can be used to predict probability survival curves for individual breast cancer patients and the effect of treatment options can be evaluated using these models. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-09-29.
Rates of Mental Disease Related to Childbearing
Authors: Thomas F. Pugh, Bal K. Jerath, William M. Schmidt, Robert B. Reed
Journal: New England Journal of Medicine (1963)

A COMPARISON of rates of mental disorder among pregnant or recently delivered women with rates in women not in these statuses appears to be one of the first priorities of an examination of the possible etiologic contribution of pregnancy or delivery to mental disorder. Aided by a recent review,1 we have examined the literature without finding such a comparison. We therefore report an attempt to estimate rates of mental illness among the female population characterized according to current reproductive status.Our interest was prompted by the following facts: the term "puerperal psychosis," although appearing in the psychiatric nosologies of England . . .
Regulations Proposed to Implement the Animal Welfare Act
Authors: M. C. Knipmeyer
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Regulations Proposed to Implement the Animal Welfare Act Get access Mary C. Knipmeyer, Ph.D. Mary C. Knipmeyer, Ph.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 10, 22 May 1989, Page 732, https://doi.org/10.1093/jnci/81.10.732 Published: 22 May 1989
P110 Does previous exacerbation history predict future exacerbations in non-CF bronchiectasis?
Authors: WS Salih, LP Poppelwell, RS Stretton, TCF Fardon, JDC Chalmers
Journal: Thorax (2013)

<h3>Introduction</h3> The British Thoracic Society bronchiectasis guidelines recommend consideration of long term antibiotic therapy in patients with 3 or more exacerbations per year. A major goal of treatment in bronchiectasis is to reduce future exacerbation risk. It is not known how reliably a past history of frequent exacerbations predicts future exacerbations in bronchiectasis. <h3>Methods</h3> Consecutive patients with non-CF bronchiectasis attending a specialist clinic in Tayside 2011–2012 were included. Patients commencing long term antibiotic therapy were excluded. Exacerbation frequency was obtained from patient histories verified against electronic antibiotic prescription data. Hospital admissions for severe exacerbations were recorded and the ability of prior exacerbation history to predict future hospital admissions assessed using the area under the receiver operator characteristic curve (AUC). <h3>Results</h3> 90 patients with bronchiectasis were included. 54% were female with a median age of 67 years. The majority had idiopathic bronchiectasis (58%), followed by allergic bronchopulmonary aspergillosis (13.3%), post-infective bronchiectasis (8%) and connective tissue disease (5%). The median FEV1 was 74% (51–94) predicted. In the first year of review, patients had a mean of 2.9 exacerbations (standard deviation 2.4), while in the second year, the mean number of exacerbations was 2.1 (standard deviation 1.9),p = 0.02. Patients with a history of 3 exacerbations in year 1 had a higher frequency of exacerbations in year 2 (2.5 vs 1.8,p = 0.03). The sensitivity of year 1 exacerbations to predict 3 or more exacerbations in year 2 was 52% (95% confidence interval 31.9–71.3%) with a specificity of 64% (50.4–75.3%) Figure 1 shows the relationships between year 1 and year 2 exacerbation frequencies. In a linear regression model, additional predictors of exacerbation in year 2 were FEV<sub>1</sub>% predicted and chronic bacterial colonisation, independent of previous exacerbation frequency. 24 patients were hospitalised for severe exacerbations in year 2. Prior exacerbation frequency was only a modest predictor of future hospitalisation risk, AUC 0.72 (95% CI 0.61–0.83), p &lt; 0.0001). (<b>Figure 1</b>) <h3>Conclusion</h3> Prior history of exacerbations predicts future exacerbations and risk of severe exacerbations, but large variations in annual exacerbation frequency are observed. Other factors may need to be considered to more accurately identify patients at risk of future exacerbations and hospital admissions.
Cyanoacrylate glue in the management of blue rubber bleb nevus syndrome
Authors: G. Mavrogenis, D. Coumaros, D. Tzilves, E. Rapti, G. Stefanidis, J. Leroy, F. Becmeur
Journal: Endoscopy (2011)

Case 1. A 16-year-old boy with blue rubber bleb nevus syndrome (BRBNS) was admitted for occult bleeding. He had a history of gastric and colonic hemangiomas treated 2 years earlier by argon plasma coagulation and alcohol injection respectively. Clinical examination showed a few hemangiomas on his back and feet ([Fig. 1]).
Dysgammaglobulinemia in the Adult Manifested as Autoimmune Hemolytic Anemia
Authors: Carl F. Hinz, John T. Boyer
Journal: New England Journal of Medicine (1963)

RECENT studies indicate that erythrocyte antibodies of isoimmune and autoimmune nature are contained in both the 7S and 19S fractions of gamma globulin.1 2 3 Support for the concept that the autoantibodies fulfill criteria as antibodies comes from identification of autoantibodies with the gamma globulins and the demonstration that certain of them are directed against specific blood-group antigens.4 Controversy has not been resolved5 whether autoantibodies develop as a result of specific antigenic stimulation or "accidentally" from production of a spectrum of abnormal proteins.In the present study an unusual antibody of anti-N specificity occurred in a patient with acquired hemolytic anemia. Characterization . . .
USEFULNESS OF RECIPROCAL CHANGES IN THE DIAGNOSIS OF MYOCARDIAL INFARCTION WITH MINIMAL ST-ELEVATION
Authors: David Marti, Eduardo Casas, José Luis Mestre, Luisa Salido, María Jesus Esteban, Jaime Pey, Marcelo Sanmartín, Rosana Hernández-Antolín, José Luis Zamorano
Journal: Journal of the American College of Cardiology (2016)
Predictive value of sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically node negative breast cancer
Authors: J. L. Jones, E. Rhei, M. A. Gadd, M. Howard-Mcnatt, K. S. Hughes, B.-A. Lesnikoski, R. L. Christian, J. T. Rabban, C. Kaelin, B. L. Smith
Journal: Journal of Clinical Oncology (2004)

606 Background: Applicability and optimal timing of sentinel node biopsy (SNB) in breast cancer patients treated with neoadjuvant therapy is not yet known. SNB prior to neoadjuvant therapy is relatively untested, while SNB after neoadjuvant therapy is associated with lower mapping success and higher false negative rates. SNB prior to neoadjuvant therapy may give data useful in guiding systemic, radiation and surgical treatment decisions. Methods: 52 T2-T4, N0 breast cancer patients who had SNB prior to neoadjuvant therapy from 7/2000 to 10/2003 were reviewed. Initial 1° tumor size, SNB pathology, clinical response to therapy and findings at definitive surgery were examined. Results: 22 patients (42%) were SNB(-) and 21 had no further axillary treatment. None have recurred locally. 1 SNB(-) patient had tumor progression during chemo and a positive axillary node dissection (ALND). 30 patients (58%) were SNB(+); to date 26 have had ALND after neoadjuvant therapy; 1 with a micromet had no further surgery. At ALND for initially SNB(+), 17 (65%) were node negative, 4(15%) had micromets <0.2cm, and only 5(19%) had residual axillary macromets. Residual tumor sizes ranged from 0–9.0cm (median 2.0cm, 5 tumors >4cm) in 21 SNB(+) with (-) or micromet-only ALND's. In 5 SNB(+) with macromets on ALND, residual tumor sizes ranged from 0.3- 5.2cm. Conclusions: There were no early axillary relapses in patients with (-)SNB's prior to neoadjuvant therapy. The majority of clinically N0 breast cancer patients with (+) SNB's prior to neoadjuvant therapy will have minimal residual axillary disease at ALND. Among SNB(+)'s, residual 1° tumor size did not predict ALND status. These data suggest it may be possible to explore less morbid alternatives to axillary dissection in clinically N0 patients undergoing neoadjuvant therapy. No significant financial relationships to disclose.
PWE-060 The Hospital Anxiety and Depression Scale (HADS) Predicts Pain and Distress at Endoscopy: Abstract PWE-060 Table 1
Authors: A J Irvine, M Kurien, R Harrold, L Taylor, D S Sanders
Journal: Gut (2013)

<h3>Introduction</h3> Tolerability of endoscopy is variable, with pain and distress influencing overall experience. Currently, there is a paucity of work evaluating distress, with no reliable tools established as predictors of endoscopic tolerability. A recent study found higher levels of discomfort during colonoscopy in patients scoring 11 or more (out of a maximum of 21) on the anxiety portion of the HADS questionnaire evaluated post-procedure.<sup>1</sup> Our study evaluates the pre-endoscopic use of HADS and its value in predicting procedural pain and distress. <h3>Methods</h3> Consecutive patients attending for clinically indicated OGD or colonoscopy were prospectively recruited between September 2011 and June 2012 at a University hospital. Prior to endoscopy, patients completed the HADS questionnaire and were familiarised with the 10-point numeric rating scale used to assess expected pain and distress and post-procedural pain and distress. Patients with high HADS anxiety scores (HADS≥11) were then compared with those with low scores (HADS≤10), with the cut off value of 11 defined in accordance with the original HADS paper.2 Data was analysed using SPSS version 20, with a Mann Whitney U test used to determine differences between procedural pain and distress scores. <h3>Results</h3> 610 patients were prospectively recruited (280 male patients, median age 56 years, range 17–90 years, 306 OGD’s), with 21% (128/610) having HADS anxiety scores &gt; 11. Of these individuals, 51% (65/128) had elevated procedural pain, with 53% (68/128) having elevated procedural distress. By comparison in patients with HADS anxiety scores &lt; 10, only 32% (154/482) had elevated procedural pain and 37% (176/482) had elevated distress. Comparisons between the two groups (HADS≥11 and those with HADS ≤10) demonstrated significant differences (p = 0.001 for pain and p &lt; 0.001 for distress). Median scores for the two groups are highlighted in Table 1. <h3>Conclusion</h3> This is the first study demonstrating how the HADS could be used to predict endoscopic tolerability, with HADS anxiety scores ≥11 associated with over a 50% chance of having procedural pain and distress. Adopting HADS into pre-endoscopy assessments could help identify patients likely to poorly tolerate endoscopy, leading to earlier consideration of sedation, analgesia and other endoscopic measures to minimise pain and distress. <h3>Disclosure of Interest</h3> None Declared. <h3>References</h3> Elphick D<i> et al.</i> Factors associated with abdominal discomfort during colonoscopy: a prospective analysis. European Journal of Gastroenterology and Hepatology. 2009 Sep; 21(9):1076–82. Zigmond AS <i>et al.</i> The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun; 67(6):361–70
TECHNICAL EFFICACY OF ULTRASOUND-GUIDED TIBIAL ARTERY END VASCULAR INTERVENTIONS FOR CHRONIC TOTAL OCCLUSION LESIONS IN CRITICAL LIMB ISCHEMIA
Authors: Kenji Makino, Yoshiaki Ito, Keisuke Hirano, Masahiro Yamawaki, Motoharu Araki, Norihiro Kobayashi, Hideyuki Takimura, Yasunari Sakamoto, Shinsuke Mori, Masakazu Tsutsumi, Takuro Takama, Hiroya Takafuji, Yohsuke Honda, Takahiro Tokuda
Journal: Journal of the American College of Cardiology (2016)
Unsuspected Lymphoma Detected on Tc-99m Sestamibi Parathyroid Scan
Authors: RICHARD J. THOMAS, JUDITH M. JOYCE, DANIEL T. MYERS, KARAN LOTFI, MICHELE ORGANIST
Journal: Clinical Nuclear Medicine (2000)

Technetium-99m complexes, specifically Tc-99m sestamibi, initially showed great promise as cardiac and parathyroid imaging agents at the time of their introduction in the 1980s. Since then, noncardiac and parathyroid applications have been expanding rapidly. The utility of Tc-99m sestamibi as a tumor imaging agent has been well demonstrated. Uptake by thyroid and bronchial carcinomas and by non-Hodgkin’s lymphoma has been documented. A 76-year-old woman was examined for evaluation of a presumed thyroid nodule. Ultrasound examination revealed a 1.1-cm nodule in the anterior left neck, which was thought to be a parathyroid adenoma. A Tc-99m sestamibi parathyroid scan showed abnormal uptake in the lateral left neck and left suprahilar region. Subsequent computed tomographic imaging and biopsy of a mesenteric soft tissue mass led to a diagnosis of malignant B-cell lymphoma.